Patent SG-11201903945X-A (SG)
Title: Reconstituted high density lipoprotein treatment of myocardial infarction
Inventor: WRIGHT SAMUEL
IPC: A61K31/70
Filed: 2017-11-10
Abstract: cccc cc O C () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 May 2018 (17.05.2018) WIPO I PCT D IV °nolo III m Elmo 110111110 Hs (10) International Publication Number WO 2018/085890 Al (51) International Patent Classification: A61K 31/56 (2006.01) A61P 3/06 (2006.01) A61K 31/198 (2006.01) A61P 9/10 (2006.01) A61K 31/70 (2006.01) (21) International Application Number: PCT/AU2017/051232 (22) International Filing Date: 10 November 2017 (10.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/420,050 10 November 2016 (10.11.2016) US 62/472,240 16 March 2017 (16.03.2017) US (71) Applicant: CSL LIMITED [AU/AU]; 45 Poplar Road, Parkville, Victoria 3052 (AU). (72) Inventors: WRIGHT, Samuel; 516 Hillside Avenue, Westfield, New Jersey 07090 (US). SHEAR, Charles; 4086 Heckler Road, Collegeville, Pennsylvania 19426 (US). D'ANDREA, Denise; 2910 Toll Gate Drive, East Norriton, Pennsylvania 19403 (US). GILLE, Andreas; 6 Milverton Street, Moonee Ponds, Victoria 3039 (AU). DUFFY, Danielle; 904 Truepenny Road, Media, Pennsyl- vania 19063 (US). (74) Agent: FISHER ADAMS KELLY CALLINANS; Level 6, 175 Eagle Street, Brisbane, Queensland 4000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: RECONSTITUTED HIGH DENSITY LIPOPROTEIN TREATMENT OF MYOCARDIAL INFARCTION Figure 1 1401 A55,5Pd ter eligibili7 01 143 Did not meet inclusion exclusion miteria 1258 .anentsr andemizN Strated by renal function 5-, S Normal renal function 6SO Slid feral in:panne, 119 C SL112 2g 421 CSL112 6g 118 Placebo ITT 195 Normal renal func - EDn 192 '.tionnalr enal function 191 Normal renal function Population 224 Nad remdimpaitment 229 Mild renal impaimem Mild renal impairment Did did 1,6, any dose of stud' drug 5 Did not receive 211V dose of 5tudv drug Did not t ereive any Lose o f srudv drug Safety 415 CSL1122 116 C SL112 fig 413 Placebo Populalion 193 222 Normal renal lUnctim Mild tenalimpalrment 190 226 Noma renal Lnction Mild r nal mpaimen, 189 224 Normal renal functiDn Mild renal impairment (57) : Reconstituted HDL formulations, methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The reconstituted HDL formulations comprise an apo lipoprotein, a lipid, a detergent and a stabilizer such as sucrose. Treatment of MI patients with repeated infusions of rHDL enhance cholesterol efflux capacity and do not produce significant alterations in liver or kidney function. The MI patient may have normal kidney function or moderate renal impairment.